KLRS Kalaris Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1754068 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY21.8%
TTM EPS YoY90.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-97.2%
ROA-51.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets46.7%
Debt / equity0.00x
Current ratio10.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $30.75M | $45.04M | $133.07M | $118.87M | $120.73M |
| SG&A expense | $15.40M | $6.69M | $48.26M | $52.33M | $49.08M |
| Operating income | -$46.15M | -$51.73M | -$199.90M | -$171.20M | -$169.82M |
| Interest expense | $1.44M | $2.70M | — | — | — |
| Pretax income | -$43.44M | -$69.17M | -$190.54M | -$168.97M | -$170.96M |
| Income tax | $0 | $0 | -$126,000 | -$265,000 | $1.01M |
| Net income | -$43.44M | -$69.17M | -$190.42M | -$168.71M | -$171.96M |
| EBITDA | -$46.14M | — | -$199.50M | -$170.48M | -$169.63M |
| EPS (basic) | -2.85 | -51.77 | -42.09 | -2.20 | -2.74 |
| EPS (diluted) | -2.85 | -51.77 | -42.09 | -2.20 | -2.74 |
| Weighted avg. shares (diluted) | 15.27M | 1.34M | 4.52M | 76.65M | 62.78M |
| Balance sheet | |||||
| Cash & equivalents | $98.05M | $1.64M | $90.12M | $106.09M | $201.66M |
| Short-term investments | $19.93M | $0 | $93.82M | $127.70M | $46.46M |
| Current assets | $118.81M | $2.61M | $187.63M | $243.05M | $253.35M |
| PP&E, net | — | — | — | $930,000 | $1.55M |
| Total assets | $121.74M | $6.16M | $190.80M | $277.08M | $286.59M |
| Current liabilities | $9.71M | $24.70M | $28.37M | $24.34M | $37.85M |
| Total liabilities | $42.92M | $56.78M | $45.02M | $52.56M | $61.33M |
| Shareholders' equity | $78.81M | -$96.62M | -$45.02M | $224.52M | $225.27M |
| Shares outstanding | 22.90M | 1.36M | 4.96M | 93.09M | 63.57M |
| Cash flow statement | |||||
| Operating cash flow | -$38.37M | -$20.67M | -$124.45M | -$142.05M | -$106.32M |
| Capital expenditure | $200,000 | — | — | — | $26,000 |
| Free cash flow | -$38.57M | — | — | — | -$106.34M |
| Investing cash flow | -$19.72M | $95.00M | $37.98M | -$80.48M | $185.98M |
| Financing cash flow | $155.01M | $19.14M | $70.50M | $126.96M | $232,000 |
| Depreciation & amortization | $13,000 | — | $398,000 | $723,000 | $189,000 |
| Stock-based compensation | $1.94M | $895,000 | $40.78M | $41.31M | $43.98M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.